Revenue: As of FY2025 Q3, the actual value is USD 3.538 M.EPS: As of FY2025 Q3, the actual value is USD -0.17.EBIT: As of FY2025 Q3, the actual value is USD -8.151 M.<h3>Segment Revenue</h3><ul><li>Net Revenue: For the three months ended September 30, 2025, net revenue was $3.5 million, an increase of 19% compared to $3.0 million for the same period in 2024. For the nine months ended September 30, 2025, net revenue was $9.6 million, an increase of 16% compared to $8.3 million for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: For the three months ended September 30, 2025, gross profit was $1.9 million, an increase of 16% compared to $1.7 million for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $5.2 million, an increase of 12% compared to $4.6 million for the same period in 2024.</li><li>Operating Loss: For the three months ended September 30, 2025, operating loss was - $8.0 million, an increase of 38% compared to - $5.8 million for the same period in 2024. For the nine months ended September 30, 2025, operating loss was - $18.1 million, an increase of 18% compared to - $15.3 million for the same period in 2024.</li><li>Net Loss: For the three months ended September 30, 2025, net loss was - $7.9 million, an increase of 37% compared to - $5.8 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $17.9 million, an increase of 17% compared to - $15.3 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $15.2 million, compared to - $14.7 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used in investing activities was - $0.1 million, compared to - $0.2 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $23.6 million, compared to $10.1 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>International Sales: For the nine months ended September 30, 2025, international sales accounted for approximately 23% of total revenue.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to grow its small-bowel-related revenues by increasing the size and effectiveness of its U.S. and international sales teams, pursuing the pediatric market, and introducing complementary products such as a capsule delivery device and patency capsule.</li><li>Non-Core Business: CapsoVision is developing its next pipeline capsule endoscope product, CapsoCam Colon, with plans to submit for FDA clearance in the second quarter of 2026 and target commercialization in the fourth quarter of 2026.</li><li>Priority: The company is focused on obtaining FDA clearance for its CapsoCam Colon capsule endoscopy solution and expanding its indicated patient population to increase its addressable market.</li></ul>

CapsoVision | 10-Q: FY2025 Q3 Revenue: USD 3.538 M